AU2018236352B2 - Methods and compositions for inducing immune responses against clostridium difficile - Google Patents

Methods and compositions for inducing immune responses against clostridium difficile Download PDF

Info

Publication number
AU2018236352B2
AU2018236352B2 AU2018236352A AU2018236352A AU2018236352B2 AU 2018236352 B2 AU2018236352 B2 AU 2018236352B2 AU 2018236352 A AU2018236352 A AU 2018236352A AU 2018236352 A AU2018236352 A AU 2018236352A AU 2018236352 B2 AU2018236352 B2 AU 2018236352B2
Authority
AU
Australia
Prior art keywords
asn
ile
gly
asp
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018236352A
Other languages
English (en)
Other versions
AU2018236352A1 (en
Inventor
David Flyer
Gregory Glenn
Ye Liu
Gale Smith
Jing-Hui Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novavax Inc
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of AU2018236352A1 publication Critical patent/AU2018236352A1/en
Application granted granted Critical
Publication of AU2018236352B2 publication Critical patent/AU2018236352B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018236352A 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile Active AU2018236352B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471636P 2017-03-15 2017-03-15
US62/471,636 2017-03-15
US201762474434P 2017-03-21 2017-03-21
US62/474,434 2017-03-21
PCT/US2018/022597 WO2018170238A2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Publications (2)

Publication Number Publication Date
AU2018236352A1 AU2018236352A1 (en) 2019-10-03
AU2018236352B2 true AU2018236352B2 (en) 2024-04-04

Family

ID=63523217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018236352A Active AU2018236352B2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Country Status (12)

Country Link
US (2) US11123419B2 (enExample)
EP (1) EP3595709A4 (enExample)
JP (2) JP7149285B2 (enExample)
KR (1) KR102640722B1 (enExample)
CN (1) CN110691609B (enExample)
AU (1) AU2018236352B2 (enExample)
BR (1) BR112019019117A2 (enExample)
CA (1) CA3056090A1 (enExample)
IL (1) IL269258B2 (enExample)
MX (1) MX2019010948A (enExample)
SG (1) SG11201908376UA (enExample)
WO (1) WO2018170238A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN110691609B (zh) * 2017-03-15 2024-04-19 诺瓦瓦克斯股份有限公司 用于诱导针对艰难梭菌的免疫应答的方法和组合物
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112867A1 (en) * 2012-01-27 2013-08-01 Merck Sharp & Dohme Corp. Vaccines against clostridium difficile comprising recombinant toxins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1999011711A1 (en) * 1997-09-04 1999-03-11 Eastman Chemical Company Thermoplastic polyurethane additives for enhancing solid state polymerization rates
WO2010017383A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
US20130039973A1 (en) * 2011-08-03 2013-02-14 Henry J. Smith Viral Immunogenic Compositions
SG10201602434UA (en) 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
EP2928489B1 (en) 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CN105451762A (zh) 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
EP3524262A1 (en) * 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
BE1022949B1 (fr) * 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
CN106220737B (zh) * 2016-07-21 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白及其在治疗艰难梭菌相关疾病中的应用
CN110691609B (zh) 2017-03-15 2024-04-19 诺瓦瓦克斯股份有限公司 用于诱导针对艰难梭菌的免疫应答的方法和组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112867A1 (en) * 2012-01-27 2013-08-01 Merck Sharp & Dohme Corp. Vaccines against clostridium difficile comprising recombinant toxins

Also Published As

Publication number Publication date
US20200085934A1 (en) 2020-03-19
CN110691609A (zh) 2020-01-14
WO2018170238A3 (en) 2018-10-18
EP3595709A4 (en) 2020-12-23
SG11201908376UA (en) 2019-10-30
RU2019132111A (ru) 2021-04-15
CN110691609B (zh) 2024-04-19
IL269258B1 (en) 2023-05-01
CA3056090A1 (en) 2018-09-20
JP2022179543A (ja) 2022-12-02
IL269258A (en) 2019-11-28
US11938179B2 (en) 2024-03-26
WO2018170238A2 (en) 2018-09-20
EP3595709A2 (en) 2020-01-22
US11123419B2 (en) 2021-09-21
MX2019010948A (es) 2020-01-09
AU2018236352A1 (en) 2019-10-03
US20220211834A1 (en) 2022-07-07
RU2019132111A3 (enExample) 2021-06-29
JP7149285B2 (ja) 2022-10-06
JP7397145B2 (ja) 2023-12-12
KR102640722B1 (ko) 2024-02-26
BR112019019117A2 (pt) 2020-05-05
IL269258B2 (en) 2023-09-01
JP2020509770A (ja) 2020-04-02
KR20190125470A (ko) 2019-11-06

Similar Documents

Publication Publication Date Title
US11938179B2 (en) Methods and compositions for inducing immune responses against Clostridium difficile
JP6351641B2 (ja) ノロウイルスに由来する免疫原性組成物および方法
CA2774640C (en) Virus like particles comprising target proteins fused to plant viral coat proteins
EP2061887B1 (en) Vlp based influenza vaccine delivery system
EP3344291A2 (en) Vaccine compositions having improved stability and immunogenicity
CN107056901A (zh) 脑膜炎双球菌组合物及其方法
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
WO2017161151A1 (en) Vaccine compositions containing modified zika virus antigens
KR20230005265A (ko) Sars-cov-2에 대한 백신 및 이의 제조
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
JP2012532626A (ja) 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
CN104560780B (zh) 产气荚膜梭菌ε毒素减毒突变体及其应用
RU2781057C2 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
RU2781057C9 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
CN117003885B (zh) H5n8禽流感广谱性疫苗的开发及其应用
US9493518B2 (en) Compositions and methods for treating clostridium difficile-associated diseases
CN116940372A (zh) 流感嗜血杆菌疫苗和使用方法
CA3131551A1 (en) Methods for preventing disease or disorder caused by rsv infection
US20240335523A1 (en) Glycoengineered Foldon Domains and Related Compositions and Methods
TWI633114B (zh) 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物
CN121494995A (zh) 一种稳定且具有正确亚复合物形成模式的猴痘病毒a30/h2融合蛋白及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)